Loroblis 16 Orodispersible Tablets – Oral Probiotic with Streptococcus salivarius K12 for Respiratory Health

Properties:
- restores eubiosis in the oral cavity, oropharynx and nasopharynx;
- streptococcus salivarius K12 produces 2 bacteriocins that have the potential to inhibit the development of pathogenic bacterial strains (for example: Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, responsible for bacterial pharyngitis and tonsillitis, acute otitis media and halitosis);
- streptococcus salivarius K12 has antiviral, anti-inflammatory and antifungal activity, supported in over 20 studies on human subjects;
- improvement of manifestations associated with upper respiratory tract infections.

Directions for use:
One tablet/day, in the evening after oral hygiene, for a minimum of 3 months (especially in the cold season and before the start of the school year).
For children over 3 years old and adults.

Precautions:
Administration is done in the evening, after oral hygiene, without consuming liquids or food.
Concomitant administration with antibiotics is unnecessary.
Contraindicated in immunocompromised patients, with chemotherapy, radiotherapy, severe leukopenia.

Ingredients:
One LOROBLIS® orodispersible tablet contains a minimum of 1x10⁹ CFU Streptococcus salivarius K12 (BLIS® K12) + vitamin D3/ cholecalciferol (200 IU).

Presentation:
16 tablets

Loroblis 16 Innergy tablets (improvement of manifestations associated with upper respiratory tract infections) is part of the category and can be administered on the recommendation of a doctor or pharmacist.
Information about Loroblis, 16 tablets, Innergy could be found in the articles: Cold versus Flu: Differences between flu and cold, Immune system, Flu vaccination in children, Flu vaccine, Viruses, COVID-19, Flu, Influenza type B, Influenza type A, Herpangina, Pneumonia, Cold, Low immunity.